Other Patients Bear The Real Cost of Herceptin

Armen Hareyan's picture

The real cost of Herceptin is born by other patients whose treatment has to be dropped to balance the books, say doctors in this week's BMJ.


New guidance from the National Institute for health and Clinical Excellence (NICE) recommends trastuzumab (Herceptin) in early breast cancer, but it provides no extra funding and does not suggest what cuts should be made to release this extra money. This leaves medical staff with difficult decisions to make.

Doctors at the Norfolk and Norwich University Hospital NHS Trust and the University of East Anglia calculated that they will have to find

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.